TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
Brief Summary: This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.


Options:
A: Arm Label: Infliximab + methotrexate (IFX + MTX); Type: EXPERIMENTAL; Interventions: Drug: Infliximab + methotrexate (IFX + MTX) | Arm Label: Methotrexate (MTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: Infliximab + methotrexate (IFX + MTX); Assigned to Arm(s): Infliximab + methotrexate (IFX + MTX) | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): Methotrexate (MTX)
B: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
C: Arm Label: psoriatic arthritis (PsA) questionnaire; Type: NO_INTERVENTION; Interventions: Procedure: lab draws and imaging | Intervention Type: PROCEDURE; Name: lab draws and imaging; Assigned to Arm(s): psoriatic arthritis (PsA) questionnaire
D: Arm Label: Intensive management; Type: EXPERIMENTAL; Interventions: Drug: Intensive management or Tight control | Arm Label: Standard management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard management - Control group | Intervention Type: DRUG; Name: Intensive management or Tight control; Assigned to Arm(s): Intensive management | Intervention Type: DRUG; Name: Standard management - Control group; Assigned to Arm(s): Standard management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
Brief Summary: To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).


Options:
A: Arm Label: eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: zopiclone 7,5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): eszopiclone 3 mg | Intervention Type: DRUG; Name: Zopiclone; Assigned to Arm(s): zopiclone 7,5mg
B: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Eszopiclone 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg | Arm Label: Eszopiclone 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg | Arm Label: Eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zolpidem Tartrate 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem Tartrate 10 mg | Intervention Type: DRUG; Name: Eszopiclone 1 mg; Assigned to Arm(s): Eszopiclone 1 mg | Intervention Type: DRUG; Name: Eszopiclone 2 mg; Assigned to Arm(s): Eszopiclone 2 mg | Intervention Type: DRUG; Name: Eszopiclone 3 mg; Assigned to Arm(s): Eszopiclone 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Zolpidem Tartrate 10 mg; Assigned to Arm(s): Zolpidem Tartrate 10 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care)
Brief Summary: This study will evaluate the effectiveness of an integrated three-part treatment program in improving the quality of care and treatment outcomes of people with hypochondriasis in primary care settings.


Options:
A: Arm Label: Psychosocial Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial Counseling | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Psychosocial Counseling; Assigned to Arm(s): Psychosocial Counseling | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation response training | Intervention Type: BEHAVIORAL; Name: Relaxation response training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Psychoeducational counseling; Assigned to Arm(s): 1
C: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Experimental Group
D: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Recommendation of care (letter to general practitioner [GP]); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension
Brief Summary: Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Intervention Type: DRUG; Name: MK8141; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 3
B: Arm Label: Aliskiren-based regimen; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide, Drug: Amlodipine | Arm Label: Ramipril-based regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Hydrochlorothiazide, Drug: Amlodipine | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren-based regimen | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril-based regimen | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril
D: Arm Label: Aliskiren 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Ramipril 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren 150 mg, Aliskiren 300 mg, Aliskiren 75 mg | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril 5 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections
Brief Summary: The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).


Options:
A: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B
B: Arm Label: Bactrim DS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trim/ Sulfa DS | Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Trim/ Sulfa DS; Assigned to Arm(s): Bactrim DS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tigecycline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ampicillin-sulbactam | Intervention Type: DRUG; Name: Tigecycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ampicillin-sulbactam; Assigned to Arm(s): 2
D: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: ceftaroline, Drug: Placebo | Arm Label: IV Vancomycin plus IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: vancomycin plus aztreonam | Intervention Type: DRUG; Name: ceftaroline; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: vancomycin plus aztreonam; Assigned to Arm(s): IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ceftaroline fosamil for Injection

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sertraline Pharmacotherapy for Alcoholism Subtypes
Brief Summary: The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-week treatment period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Escitalopram plus acamprosate; Type: EXPERIMENTAL; Interventions: Drug: acamprosate, Drug: escitalopram, Behavioral: Medical management | Arm Label: Escitalopram plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: escitalopram, Behavioral: Medical management, Drug: Placebo | Intervention Type: DRUG; Name: acamprosate; Assigned to Arm(s): Escitalopram plus acamprosate | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: BEHAVIORAL; Name: Medical management; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Escitalopram plus placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine | Arm Label: C; Type: SHAM_COMPARATOR; Interventions: Other: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine | Intervention Type: OTHER; Name: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed; Assigned to Arm(s): A | Intervention Type: OTHER; Name: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine; Assigned to Arm(s): B | Intervention Type: OTHER; Name: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine; Assigned to Arm(s): C
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine-XR | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Venlafaxine-XR; Assigned to Arm(s): C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)
Brief Summary: A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected. Currently used clinical tests can only tell us how much the vessel is blocked by the plaque and not how inflamed (i.e. dangerous) it is. This new method of scanning using magnetic resonance imaging (MRI) and a special agent called Sinerim can identify inflamed plaques. This study will evaluate patients with plaques in their arteries in their neck at risk of strokes to see whether treatment with a cholesterol-lowering drug called atorvastatin can reduce the amount of inflammation within the artery wall within the first three months of treatment. If this effect can be measured using MRI scanning with the use of Sinerim then the results of this study will provide additional clinical validation of the use of MRI scanning combined with agents such as Sinerem®.


Options:
A: Arm Label: Evolocumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Evolocumab, Other: lipid-lowering therapy (LLT) | Arm Label: Standard; Type: PLACEBO_COMPARATOR; Interventions: Other: lipid-lowering therapy (LLT) | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: OTHER; Name: lipid-lowering therapy (LLT); Assigned to Arm(s): Evolocumab, Standard
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS
D: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)
Brief Summary: A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected. Currently used clinical tests can only tell us how much the vessel is blocked by the plaque and not how inflamed (i.e. dangerous) it is. This new method of scanning using magnetic resonance imaging (MRI) and a special agent called Sinerim can identify inflamed plaques. This study will evaluate patients with plaques in their arteries in their neck at risk of strokes to see whether treatment with a cholesterol-lowering drug called atorvastatin can reduce the amount of inflammation within the artery wall within the first three months of treatment. If this effect can be measured using MRI scanning with the use of Sinerim then the results of this study will provide additional clinical validation of the use of MRI scanning combined with agents such as Sinerem®.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)
Brief Summary: A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected. Currently used clinical tests can only tell us how much the vessel is blocked by the plaque and not how inflamed (i.e. dangerous) it is. This new method of scanning using magnetic resonance imaging (MRI) and a special agent called Sinerim can identify inflamed plaques. This study will evaluate patients with plaques in their arteries in their neck at risk of strokes to see whether treatment with a cholesterol-lowering drug called atorvastatin can reduce the amount of inflammation within the artery wall within the first three months of treatment. If this effect can be measured using MRI scanning with the use of Sinerim then the results of this study will provide additional clinical validation of the use of MRI scanning combined with agents such as Sinerem®.


Options:
A: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before
B: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A
C: Arm Label: Tirofiban; Type: EXPERIMENTAL; Interventions: Drug: Tirofiban Injection, Drug: Clopidogrel, Drug: Acetylsalicylic acid, Drug: Fondaparinux | Intervention Type: DRUG; Name: Tirofiban Injection; Assigned to Arm(s): Tirofiban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Tirofiban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Tirofiban | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Tirofiban
D: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: D